PHILADELPHIA CHROMOSOME IN PRETHERAPEUTIC CASES OF CHRONIC MYELOGENOUS LEUKEMIA
Chronic myeloid leukemia (CML) is a clonal myel0 proliferative disorder due to neoplastic transformation of myeloid stem cells. The characteristic Philadelphia Chromosome translocation t(9:22) (q 34: q11) juxta poses the c-abl oncogene from chromosome 9 with break point cluster region (bcr) on chromosome 22 resulting in the generation of aberrant bcr/abl transcripts. The abnormal bcr/abl tyrosine kinase gene product has enhanced activity compared to the wild type c-abl tyrosine kinase and is believed central to the pathogenesis of CML. Most of the patients in chronic phase who are treated with cytotoxic agents eventually develop a fatal blast phase that is the end stage in which the patient usually fails to respond combination chemotherapy and only treatment remain after that is allogenic bone marrow transplantation. Since the philadelphia chromosome is the most consistant abnormality in CML patients and as it possess both diagnostic as well as prognostic importance, it’s detection is mandatory to establish the diagnosis of CML and for planning of chemotherapy. Our study is a preliminary work to...
Read More